Remove Genomics Remove Pharma Companies Remove Vaccination Remove Vaccine
article thumbnail

Open science, genomics, and the quiet revolution in our approach to pharma

Drug Discovery World

Evan Floden , CEO of Seqera Labs examines how data sharing platforms are impacting cancer and genomics research. Increasingly, major collaborative life sciences projects, like the Human Genome Project or Human Cell Atlas, are driving advancements and organisations – both public and private – are taking note.

Genome 52
article thumbnail

Johnson & Johnson Begins Largest Late-Stage Trial To-Date for COVID-19 Vaccine

XTalks

With vaccine trials for COVID-19 ramping up and entering late stages, Johnson & Johnson has announced plans for what will be the largest Phase III trial so far for a vaccine against the novel coronavirus. This is double the enrollment that vaccine makers Moderna and Pfizer have planned for their Phase III trials.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

FTA for Gannex’s ASC4; Disappointment for Incyte’s Ruxolitinib; Historic win for Pfizer, BioNTech’s COVID Vaccine; Alexion buyout; the debut of InnoSkel

Delveinsight

Gannex Pharma has received Fast Track designation approval from FDA for its drug candidate ASC42 for non-alcoholic steatohepatitis (NASH). The FTA designation will help the pharma company to advance its research and development in the NASH landscape and help its commercialization in the market.

article thumbnail

Sophia Genetics launches AI tool to find COVID-19 ‘unknowns’

pharmaphorum

The data mining tool will be used to try to unearth some of the many unknowns with the virus, using next-generation sequencing (NGS) to see how the genome of SARS-CoV-2 changes over time, along with patient genetic information, results of lung and CT scans, and other clinical data.

Genetics 135
article thumbnail

Nine new industry collaborations driving drug discovery forward

Drug Discovery World

SpyBiotech and the University of Oxford Biotechnology company SpyBiotech and University of Oxford have entered a research agreement for the development of a vaccine against Epstein-Barr virus (EBV). We see a great need for a vaccine against EBV.”

Drugs 52
article thumbnail

Join DDW for the SLAS2024 Ignite Theater ‘Innovation from lab to patient’

Drug Discovery World

As a vaccine immunologist Kanekiyo’s primary research interests are structure-based vaccine design, viral immunity, and host-pathogen interplay. As a vaccine immunologist Kanekiyo’s primary research interests are structure-based vaccine design, viral immunity, and host-pathogen interplay.

Protein 52
article thumbnail

Top 10 Fastest Growing Biotech Companies in 2023

XTalks

These companies were identified through The Americas’ Fastest-Growing Companies 2023 list by the Financial Times. In 2023, Moderna is poised to achieve sales figures ranging from $6 billion to $8 billion, contingent on the prevailing COVID-19 vaccination rates in the US. vaccine, mRNA-1273.815.

Genetics 111